Literature DB >> 16045459

Tuberculosis and HIV interaction in sub-Saharan Africa: impact on patients and programmes; implications for policies.

Dermot Maher1, Anthony Harries, Haileyesus Getahun.   

Abstract

Sub-Saharan Africa carries the overwhelming share of the global burden of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) and of HIV-associated tuberculosis (TB). The impact of HIV on TB patients and programmes has implications for TB control policies. The impact on patients includes the effect of HIV on diagnosis and on the patterns of HIV-related TB, the response of HIV-infected TB patients to TB treatment, the benefits of antiretroviral therapy (ART), and the quality and continuity of care for TB patients. The impact on national TB programmes (NTPs) includes increased case load, impaired NTP performance, increased need for access to ART and difficulties in reaching TB control targets. Implications for policies include the need to promote TB and HIV/AIDS programme collaboration, aimed at improving NTP performance (TB case-finding and treatment outcomes), quality and continuity of care, and monitoring and interpretation of progress towards TB control targets. In order to provide the recommended international standard of care for TB patients, clinicians need to be aware of the impact of HIV on TB patients and programmes and the implications for the policies that provide the framework for this standard. Conversely, policy-makers need to understand the impact of HIV on TB patients and programmes. This can help to ensure a firm evidence base for TB control policies aiming at the high standard of patient care that is at the heart of TB and HIV programmes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16045459     DOI: 10.1111/j.1365-3156.2005.01456.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  34 in total

1.  Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations.

Authors:  Ted Cohen; Marc Lipsitch; Rochelle P Walensky; Megan Murray
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

2.  High mortality in tuberculosis patients despite HIV interventions in Swaziland.

Authors:  G Mchunu; J van Griensven; S G Hinderaker; W Kizito; W Sikhondze; M Manzi; T Dlamini; A D Harries
Journal:  Public Health Action       Date:  2016-06-21

Review 3.  Tuberculosis and HIV co-infection: screening and treatment strategies.

Authors:  Kartik K Venkatesh; Soumya Swaminathan; Jason R Andrews; Kenneth H Mayer
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

4.  Safety and tolerability of sputum induction in adolescents and adults with suspected pulmonary tuberculosis.

Authors:  H D Geldenhuys; W Kleynhans; N Buckerfield; M Tameris; Y Gonzalez; H Mahomed; G Hussey; W Hanekom; M Hatherill
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-28       Impact factor: 3.267

5.  The mental health impact of AIDS-related mortality in South Africa: a national study.

Authors:  L Myer; S Seedat; D J Stein; H Moomal; D R Williams
Journal:  J Epidemiol Community Health       Date:  2008-12-15       Impact factor: 3.710

6.  Cost and cost-effectiveness of smear-positive tuberculosis treatment by Health Extension Workers in Southern Ethiopia: a community randomized trial.

Authors:  Daniel G Datiko; Bernt Lindtjørn
Journal:  PLoS One       Date:  2010-02-17       Impact factor: 3.240

7.  Intensified case finding for tuberculosis in prevention of mother-to-child transmission programs: a simple and potentially vital addition for maternal and child health.

Authors:  Andrea Deluca; Richard E Chaisson; Neil A Martinson
Journal:  J Acquir Immune Defic Syndr       Date:  2009-02-01       Impact factor: 3.731

8.  Determination of Sites Involved, HIV Co-Infection & Utility of Diagnostic Modalities in EPTB.

Authors:  Aruna Shanmuganathan; Srinivasan R; Thilagavathy G; Satishkumar D; Sidduraj C; Bonny James
Journal:  J Clin Diagn Res       Date:  2013-08-01

9.  High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe.

Authors:  Christopher Nyakutira; Daniel Röshammar; Emmanuel Chigutsa; Prosper Chonzi; Michael Ashton; Charles Nhachi; Collen Masimirembwa
Journal:  Eur J Clin Pharmacol       Date:  2007-12-05       Impact factor: 2.953

10.  Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with TB and HIV.

Authors:  Payam Tabarsi; Ali S Saber-Tehrani; Parvaneh Baghaei; Mojgan Padyab; Davood Mansouri; Majid Amiri; Mohammad Reza Masjedi; Frederick L Altice
Journal:  J Int AIDS Soc       Date:  2009-07-16       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.